查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1321527

甘露醇市場 - 預測 2023-2028

Mannitol Market - Forecasts from 2023 to 2028
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 139 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

2021 年甘露醇市場價值為 2.094 億美元。

甘露醇是一種糖醇或糖醇，具有低溶解度和吸濕性，既可用作甜味劑，也可用作藥物。 甘露醇天然存在於樹皮、新鮮蘑菇、褐藻、海藻以及大多數水果和蔬菜中。 人工生產的甘露醇通常是通過氫化果糖來生產的，而果糖是從澱粉或蔗糖中獲得的。 甘露醇是一種低熱量甜味劑，因為它在腸道中吸收很差。 它用於通過降低眼內壓和增加顱內壓來治療青光眼。 它通過注射或吸入給藥。 效果通常在 15 分鐘內開始，持續長達 8 小時。

消費者的生活質量顯著改善，主要得益於個人收入的增加。 隨著消費者健康意識的增強，國民的飲食習慣發生了顯著變化。 此外，公司投入大量時間和資源來開發由天然成分組成或專門為促進健康而設計的產品。 因此，對低熱量天然甜味劑的需求不斷增長正在推動預測期內全球甘露醇市場的增長。 不斷增長的糖尿病人口也推動了擴張，因為甘露醇對消費者的血糖水平幾乎沒有影響。

然而，複雜的法律、限制、可能的副作用和知識的缺乏正在限制市場的增長。

食品、飲料和製藥行業對甘露醇的需求不斷增加，正在加速市場增長。

甘露醇在各種糖果產品中用作甜味劑，特別是無糖產品。 由於其溶解度低、潛熱高，甘露醇廣泛用於薄荷糖和泡泡糖的生產。 甘露醇吸濕性極低，在濕度達到98%之前不會吸收空氣中的水分，非常適合用作硬糖、乾果、巧克力塗層、口香糖等的塗層。 甘露醇優異的風味和質地使其成為咀嚼片的首選賦形劑。

甘露醇的血糖指數比蔗糖低，是糖尿病患者的甜味劑。 因此，肥胖、糖尿病、代謝綜合徵患者數量的增加以及消費者意識的提高正在導致甘露醇的積極擴張。 據 IDF 稱，到 2021 年，糖尿病將影響 5.37 億人。 預測顯示，到 2030 年，這一數字將增至 6.43 億，到 2045 年將增至 7.83 億。 5.41 億人面臨患 2 型糖尿病的風險。

甘露醇還具有治療用途。 它用於通過降低眼內壓來治療青光眼，並且在頭部外傷的情況下，它可以降低顱內壓。 甘露醇在歐盟 (EU) 被批准用於治療 18 歲及以上成人的囊性纖維化。 它還可用於治療尿量減少的腎衰竭、降低眼壓、促進某些毒素的排除以及治療液體瀦留。 因此，青光眼等疾病患病率的上升可能會進一步促進甘露醇市場的擴大。 根據疾病預防控制中心的數據，大約有 300 萬美國人患有青光眼。 最常見的青光眼類型是開角型青光眼，它會導致眼壓升高。

預計在預測期內，亞太地區將在全球甘露醇市場中佔據重要份額。

預計亞太地區將佔據甘露醇市場的很大份額。 由於消費者健康意識的增強、城市化進程的加快和可支配收入的增加，該地區將在預測期內實現高速增長。 甘露醇在中國和印度等新興市場的需求量很大。 由於飲食習慣的改變以及對低熱量產品和飲料的需求不斷增長，該地區的市場正在增長。 甘露醇不會影響血糖水平，使其成為糖尿病患者的絕佳選擇。 因此，印度和中國等國家糖尿病患病率的上升正在推動這一領域的需求。 根據國際糖尿病聯盟的數據，到 2021 年，印度將有 8.3% 的成年人（即超過 7400 萬人）患有糖尿病。 到 2045 年，這一數字預計將增至 1.248 億。 到2021年，中國13%的成年人，即超過1.4億人將患有糖尿病。 到 2045 年，這一數字預計將增至 1.744 億。 此外，石家莊華旭藥業有限公司、新華集團有限公司和山東聯盟國際貿易有限公司等主要市場參與者的滲透也推動了甘露醇在該地區的增長。 亞太地區的主要市場是印度、中國、日本、韓國、泰國、台灣和印度尼西亞。

市場趨勢：

  • 2022 年 11 月，領先的製藥和營養輔料製造商羅蓋特 (Roquette) 宣布推出兩款用於直接壓片的下一代甘露醇解決方案：Pearitol CR-H 和 Pearlitol 200 GT。 這兩種輔料都是專門為解決製藥行業獨特的配方挑戰而開發的，幫助製造商優化直接壓片技術，實現控釋片和微片等創新，並正在擴展到各個應用領域。
  • 2020 年 3 月，SPI Pharma 宣布將 Mannogem XL Opal、Mannogem XL Ruby、Mannogem Emerald 和 Mannogem Onyx 添加到 Mannogem 甘露醇產品組合中，用於多種患者友好型口服劑型。 SPI Pharma 的新藥典“甘露醇”牌號適合配製口腔崩解片和咀嚼片等患者友好劑型，可減小片劑尺寸並縮短崩解時間，從而提高患者的依從性。 它還增加了解決複雜配方挑戰的選擇，例如含量均勻性、低原料藥可壓縮性和卓越的有機性。

內容

第一章簡介

  • 市場概覽
  • 市場定義
  • 調查範圍
  • 市場細分
  • 貨幣
  • 先決條件
  • 基準年和預測年的時間表

第二章研究方法

  • 調查數據
  • 調查過程

第 3 章執行摘要

  • 研究亮點

第 4 章市場動態

  • 市場驅動因素
  • 市場製約因素
  • 波特五力分析
  • 行業價值鏈分析

第五章全球甘露醇市場：按形式

  • 簡介
  • 粉末
  • 顆粒

第 6 章全球甘露醇市場：按應用分類

  • 簡介
  • 食物
  • 醫學
  • 工業
  • 其他

第 7 章：全球甘露醇市場：按地區

  • 簡介
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 其他
  • 中東/非洲
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 以色列
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 印度尼西亞
    • 泰國
    • 其他

第8章競爭環境與分析

  • 主要公司及戰略分析
  • 新興公司和市場盈利能力
  • 合併、收購、協議和合作
  • 供應商競爭力矩陣

第9章公司簡介

  • Roquette Freres Company
  • Cargill, Incorporated.
  • Ingredion Incorporated
  • SPI Pharma
  • Singsino Group Ltd.,
  • Merck Millipore Corporation
  • Bright Moon Seaweed
簡介目錄
Product Code: KSI061615253

The mannitol market was valued at US$209.4 million in 2021.

Mannitol is a type of sugar polyol or sugar alcohol with low solubility and hygroscopicity and is used as both a sweetener and a drug. Mannitol is naturally found in tree bark, fresh mushrooms, brown algae, seaweed, and most fruits and vegetables. Artificially mannitol is generally manufactured by hydrogenating fructose, which is derived from starch or sucrose. Since the intestines absorb it poorly, mannitol is a low-calorie sweetener. It is used to treat glaucoma by lowering ocular pressure and increasing intracranial pressure. It is administered medically by injection or inhalation. The effects usually start within 15 minutes and extend to 8 hours.

The consumer's quality of life has greatly improved, owing mostly to increased personal income. As a result of rising health consciousness among consumers, the population's eating habits have shifted substantially. Furthermore, firms are investing a lot of time and resources in developing products composed of natural ingredients and specialized goods that improve health. As a result, rising demand for low-calorie natural sweeteners is propelling the growth of the global market for mannitol throughout the projected period. The growing diabetic population is also driving expansion since mannitol has little to no effect on the consumer's blood sugar level.

However, complex laws, restrictions, possible side effects, and a lack of knowledge are restraining the market growth.

The growing demand for mannitol from the food & beverage and pharmaceutical industries is accelerating the market growth.

Mannitol is used as a sweetener in various confectionary goods, especially sugar-free products. Due to low solubility and high latent heat, mannitol is extensively used to produce mint candies and bubble gums. It has a very low hygroscopicity, meaning that it does not absorb water from the air until the humidity level reaches 98 percent, which makes it an excellent covering for hard candies, dried fruits, chocolate coatings, and chewing gums. Mannitol's excellent flavor and texture make it a preferred excipient for chewable tablets.

Mannitol has a lower glycemic index than sucrose and is a sweetener for diabetic patients. Therefore an increasing number of cases of obesity, diabetes, and metabolic syndrome, along with improved consumer awareness, has resulted in a positive expansion of mannitol. Diabetes has affected 537 million people in 2021, according to the IDF. According to forecasts, this figure is expected to rise to 643 million by 2030 and 783 million by 2045. 541 million people are at risk of developing type 2 diabetes.

Mannitol also has therapeutic applications associated with it. It is used to treat glaucoma by lowering ocular pressure and also reduces increased intracranial pressure in case of head trauma. Mannitol is approved in the European Union for treating cystic fibrosis in adults aged 18 and up. It may also treat renal failure with reduced urine production, lower eye pressure, promote the removal of certain toxins, and treat fluid buildup. Therefore, the rising prevalence of diseases such as glaucoma will even further contribute to the market expansion of mannitol. According to CDC data, Glaucoma affects around 3 million Americans. The most common type of glaucoma is open-angle, which causes increasing ocular pressure.

Asia Pacific is anticipated to hold a significant share of the global mannitol market during the forecast period.

Asia Pacific region is anticipated to hold a significant market share in mannitol. This region will witness high growth during the forecast period due to the rising health copiousness among consumers, increased urbanization, and rising disposable income. Mannitol is in high demand in rising markets such as China and India. This region's market is expanding due to changing eating habits and rising demand for low-calorie products and drinks. Mannitol does not affect blood sugar levels, making them an excellent choice for diabetic individuals. As a result, increased diabetes incidence in countries such as India and China is driving demand in this area. According to the International Diabetes Federation, 8.3 percent of Indian adults, or more than 74 million people, have been affected by diabetes in 2021. By 2045, this figure is predicted to rise to 124.8 million. Diabetes affected 13 percent of Chinese adults, or more than 140 million individuals, in 2021. By 2045, this figure is predicted to rise to 174.4 million. In addition, the prevalence of key market players such as Shijiazhuang Huaxu Pharmaceutical Co., Ltd., Singsino Group Ltd., and Shandong Lianmeng International Trade Co are also spurring the growth of mannitol in this region. Prime markets in the Asia Pacific region are India, China, Japan, South Korea, Thailand, Taiwan, and Indonesia.

Market Developments:

  • In November 2022, Roquette, a major pharmaceutical and nutraceutical excipients manufacturer, introduced two next-generation mannitol solutions for direct compression: Pearlitol CR-H and Pearlitol 200 GT. Both excipients were created specifically to address unique drug formulation issues in the pharmaceutical industry, assisting manufacturers in optimizing direct compression techniques and expanding into innovative application areas such as controlled-release tablets and tiny tabs.
  • In March 2020, SPI Pharma announced the addition of Mannogem XL Opal, Mannogem XL Ruby, Mannogem Emerald, and Mannogem Onyx to its portfolio of Mannogem Mannitol products for usage in numerous patient-friendly oral dose forms. SPI Pharma's new compendial mannitol grades are suited for the formulation of patient-friendly dosage forms such as orally-disintegrating tablets and chewable, with smaller tablet sizes and faster disintegration times, improving patient compliance. They increase the number of choices for resolving challenges with complex formulations, such as content consistency, low API compressibility, and better organoleptic.

Market Segmentation:

By Form

  • Powder
  • Granules

By Application

  • Food
  • Pharmaceuticals
  • Industrial
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Research Process

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. GLOBAL MANNITOL MARKET, BY FORM

  • 5.1. Introduction
  • 5.2. Powder
  • 5.3. Granules

6. GLOBAL MANNITOL MARKET, BY APPLICATION

  • 6.1. Introduction
  • 6.2. Food
  • 6.3. Pharmaceuticals
  • 6.4. Industrial
  • 6.5. Others

7. GLOBAL MANNITOL MARKET, BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. United States
    • 7.2.2. Canada
    • 7.2.3. Mexico
  • 7.3. South America
    • 7.3.1. Brazil
    • 7.3.2. Argentina
    • 7.3.3. Others
  • 7.4. Europe
    • 7.4.1. United Kingdom
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Others
  • 7.5. Middle East and Africa
    • 7.5.1. Saudi Arabia
    • 7.5.2. UAE
    • 7.5.3. Israel
    • 7.5.4. Others
  • 7.6. Asia Pacific
    • 7.6.1. Japan
    • 7.6.2. China
    • 7.6.3. India
    • 7.6.4. South Korea
    • 7.6.5. Indonesia
    • 7.6.6. Thailand
    • 7.6.7. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Emerging Players and Market Lucrativeness
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Vendor Competitiveness Matrix

9. COMPANY PROFILES

  • 9.1. Roquette Freres Company
  • 9.2. Cargill, Incorporated.
  • 9.3. Ingredion Incorporated
  • 9.4. SPI Pharma
  • 9.5. Singsino Group Ltd.,
  • 9.6. Merck Millipore Corporation
  • 9.7. Bright Moon Seaweed